daunorubicin has been researched along with mart-1 antigen in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (50.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Kono, M; Song, HZ; Tomita, Y | 1 |
| Dunn, IS; Haggerty, TJ; Kurnick, JT; Martin, S; Newton, EE; Riley, JL; Rose, LB | 1 |
2 other study(ies) available for daunorubicin and mart-1 antigen
| Article | Year |
|---|---|
Establishment of a screening system for chemicals that upregulate a melanoma antigen, Melan-A/MART-1.
Topics: Antigens, Neoplasm; Cell Line, Tumor; Cloning, Molecular; Cytochalasin D; Daunorubicin; DNA Primers; Doxorubicin; Flow Cytometry; Gene Expression Regulation, Neoplastic; Green Fluorescent Proteins; Humans; Immunotherapy; MART-1 Antigen; Melanoma; Neoplasm Proteins; Promoter Regions, Genetic; Reverse Transcriptase Polymerase Chain Reaction | 2009 |
Topoisomerase inhibitors modulate expression of melanocytic antigens and enhance T cell recognition of tumor cells.
Topics: Antigen Presentation; CD8-Positive T-Lymphocytes; Coculture Techniques; Daunorubicin; DNA Topoisomerases; Enzyme Inhibitors; Gene Expression Regulation, Neoplastic; Glioma; Humans; Immunotherapy; Interferon-gamma; Interleukin-2; Jurkat Cells; Lymphocyte Activation; MART-1 Antigen; Melanoma; Receptors, Antigen, T-Cell; Transgenes | 2011 |